Lv1
40 积分 2024-09-05 加入
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
1个月前
已完结
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
8个月前
已完结
皖公网安备34019202002308
